Viewray Inc (NASDAQ:VRAY) CEO Scott William Drake Purchases 131,260 Shares

Viewray Inc (NASDAQ:VRAY) CEO Scott William Drake purchased 131,260 shares of the company’s stock in a transaction on Tuesday, August 13th. The shares were purchased at an average price of $3.81 per share, with a total value of $500,100.60. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Shares of VRAY stock traded up $0.54 during trading hours on Tuesday, reaching $4.01. The company had a trading volume of 6,294,559 shares, compared to its average volume of 1,389,939. The company has a quick ratio of 3.21, a current ratio of 4.28 and a debt-to-equity ratio of 0.47. Viewray Inc has a twelve month low of $2.76 and a twelve month high of $10.73. The stock has a market capitalization of $305.29 million, a P/E ratio of -4.09 and a beta of 0.79. The company’s fifty day simple moving average is $8.26.

Viewray (NASDAQ:VRAY) last posted its earnings results on Thursday, August 8th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.09). The company had revenue of $30.17 million during the quarter, compared to analyst estimates of $25.92 million. Viewray had a negative net margin of 128.13% and a negative return on equity of 62.98%. Viewray’s quarterly revenue was up 83.5% compared to the same quarter last year. During the same quarter last year, the business posted ($0.30) EPS. Research analysts forecast that Viewray Inc will post -1.01 earnings per share for the current year.



Institutional investors and hedge funds have recently modified their holdings of the stock. HighTower Advisors LLC acquired a new stake in Viewray during the second quarter worth about $348,000. Parametric Portfolio Associates LLC acquired a new stake in Viewray during the second quarter worth about $123,000. Northern Trust Corp grew its position in Viewray by 9.8% during the second quarter. Northern Trust Corp now owns 940,860 shares of the company’s stock worth $8,289,000 after buying an additional 83,734 shares in the last quarter. King Luther Capital Management Corp grew its position in Viewray by 49.6% during the second quarter. King Luther Capital Management Corp now owns 347,890 shares of the company’s stock worth $3,065,000 after buying an additional 115,385 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its position in Viewray by 15.9% during the second quarter. Bank of New York Mellon Corp now owns 336,089 shares of the company’s stock worth $2,961,000 after buying an additional 46,115 shares in the last quarter.

VRAY has been the subject of a number of recent research reports. TheStreet lowered Viewray from a “c-” rating to a “d” rating in a research note on Friday, May 3rd. Zacks Investment Research lowered Viewray from a “hold” rating to a “sell” rating in a research note on Friday. Mizuho reiterated a “buy” rating and issued a $9.00 target price on shares of Viewray in a research note on Sunday. Piper Jaffray Companies initiated coverage on Viewray in a research note on Tuesday, June 18th. They issued an “overweight” rating and a $15.00 target price for the company. Finally, Jefferies Financial Group lowered their target price on Viewray from $14.00 to $7.00 and set a “buy” rating for the company in a research note on Friday. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and eight have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $11.95.

About Viewray

ViewRay, Inc designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered.

Recommended Story: Buy Rating

Insider Buying and Selling by Quarter for Viewray (NASDAQ:VRAY)

Receive News & Ratings for Viewray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viewray and related companies with MarketBeat.com's FREE daily email newsletter.